BIOLOGICAL · Unmapped registry intervention
JANX007
Find medicine records ·
Find other trials using this name
Clinical trial
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Darolutamide
Normalized identity: darolutamideView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Castration Resistant Prostatic Cancerunresolved
Interventions
JANX007BIOLOGICAL
DarolutamideDRUG · verified · RxNorm: darolutamide
Sponsors & collaborators
Janux Therapeuticslead sponsor
Mapped research locations
New YorkNew York, United States3Los AngelesCalifornia, United States2DallasTexas, United States2HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05519449 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.